Ultragenyx Pharmaceutical to Sell Priority Review Voucher for $203 Million
Ultragenyx Pharmaceutical announced it will sell a rare pediatric disease priority review voucher for $203 million, following FDA approval of its treatment for mucopolysaccharidosis type IIIA. The deal is pending customary closing conditions, including antitrust review.
How this was made
The 30-second read
Why it matters
This is a company-specific monetization of a regulatory asset following FDA approval of Fayuvi for mucopolysaccharidosis type IIIA, with a disclosed $203 million sale price and an HSR waiting-period condition.
Market read
Disclosed PRV sale price and FDA-triggered PRV receipt create a tangible, time-sensitive catalyst for the issuer’s cash and valuation narrative.
What to watch
Traders may want to monitor whether the PRV sale affects guidance, cash runway, or future development funding, none of which is detailed here.
Background
FDA priority review vouchers can be monetized by eligible sponsors after FDA approval of a qualifying therapy; the voucher sale is typically subject to standard deal closing conditions.
Ticker impact
Ultragenyx (RARE) says it will sell a rare pediatric disease PRV for $203 million after FDA approval of Fayuvi for mucopolysaccharidosis type IIIA.
Likely positive bias as investors price in the $203 million PRV proceeds subject to customary closing conditions.
The article discloses a specific PRV sale price and ties it to an FDA approval event, but provides no details on timing, net proceeds, or accounting treatment.
Market effects
Highlights ongoing monetization of FDA priority review vouchers in rare disease, reinforcing a financing pathway for biotech with approved assets.
Limited, primarily affects US biotech sentiment rather than broad regional risk.
Low, as PRVs are US FDA-specific and the disclosed event is company-specific.
Counterpoint
The headline PRV price may not translate 1:1 into near-term equity value if closing timing slips or proceeds are offset by transaction costs or prior obligations.
Key entities
- companyUltragenyx Pharmaceutical
Seller of a priority review voucher for $203 million, tied to FDA approval of Fayuvi.
- regulatorFood and Drug Administration (FDA)
Approved Fayuvi, triggering receipt of the PRV.
- productFayuvi rebisufligene etisparvovec-hopf
FDA-approved treatment for mucopolysaccharidosis type IIIA that underpins the PRV.
